91 related articles for article (PubMed ID: 19812609)
1. Targeting human glioma cells using HSV-1 amplicon peptide display vector.
Ho IA; Miao L; Sia KC; Wang GY; Hui KM; Lam PY
Gene Ther; 2010 Feb; 17(2):250-60. PubMed ID: 19812609
[TBL] [Abstract][Full Text] [Related]
2. Targeting HSV amplicon vectors.
Grandi P; Spear M; Breakefield XO; Wang S
Methods; 2004 Jun; 33(2):179-86. PubMed ID: 15121173
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
4. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide.
Argnani R; Boccafogli L; Marconi PC; Manservigi R
Gene Ther; 2004 Jul; 11(13):1087-98. PubMed ID: 15057264
[TBL] [Abstract][Full Text] [Related]
5. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
8. HSV-1 virions engineered for specific binding to cell surface receptors.
Grandi P; Wang S; Schuback D; Krasnykh V; Spear M; Curiel DT; Manservigi R; Breakefield XO
Mol Ther; 2004 Mar; 9(3):419-27. PubMed ID: 15006609
[TBL] [Abstract][Full Text] [Related]
9. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.
Sia KC; Wang GY; Ho IA; Khor HY; Miao L; Hui KM; Lam PY
J Virol Methods; 2007 Feb; 139(2):166-74. PubMed ID: 17074404
[TBL] [Abstract][Full Text] [Related]
10. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
Johnston KM; Jacoby D; Pechan PA; Fraefel C; Borghesani P; Schuback D; Dunn RJ; Smith FI; Breakefield XO
Hum Gene Ther; 1997 Feb; 8(3):359-70. PubMed ID: 9048203
[TBL] [Abstract][Full Text] [Related]
11. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
14. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
15. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
Shah K; Tang Y; Breakefield X; Weissleder R
Oncogene; 2003 Oct; 22(44):6865-72. PubMed ID: 14534533
[TBL] [Abstract][Full Text] [Related]
16. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov NG; Fraefel C; Breakefield XO
Hum Gene Ther; 2000 Jul; 11(10):1429-38. PubMed ID: 10910140
[TBL] [Abstract][Full Text] [Related]
17. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
18. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells.
Trybala E; Olofsson S; Mårdberg K; Svennerholm B; Umemoto K; Glorioso JC; Bergström T
Antiviral Res; 2004 Jun; 62(3):125-34. PubMed ID: 15130536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
